查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854167

尿道感染感染檢測市場依檢測類型、技術、最終用戶、通路和樣本類型分類－2025-2032年全球預測

Urinary Tract Infection Testing Market by Test Type, Technology, End User, Distribution Channel, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，尿道感染檢測市場規模將成長 21.5 億美元，複合年成長率為 4.90%。

關鍵市場統計數據
基準年2024年 14.7億美元
預計年份：2025年 15.4億美元
預測年份 2032 21.5億美元
複合年成長率 (%) 4.90%

為決策者提供一個簡明框架，闡述臨床需求、技術進步和供應鏈動態如何重塑尿道感染感染檢測路徑。

本執行摘要首先清楚闡述了尿道感染感染診斷領域的演變，其中臨床重點、技術創新和供應鏈現狀相互交織，共同影響醫療機構的決策。診斷管理、對快速準確病原體鑑定的日益重視以及遏制抗菌素抗藥性的迫切需求，正促使臨床醫生、實驗室技術人員和採購負責人重新調整檢測評估方式。因此，診斷路徑正從經驗性治療轉向基於更快速、更特異性的檢測方法的實證介入。

引言概述了該領域的主要變革方向，包括自動化和分子化平台的技術成熟、即時檢測解決方案的普及以及簡化樣本到結果時間線的數位化工作流程的整合。引言也探討了這些診斷技術的應用場景，從醫院和診斷實驗室到診所網路和居家照護，並強調了互通性、品質保證和可擴展實施的必要性。本部分將近期進展置於更廣泛的臨床、監管和經濟狀況下進行分析，幫助讀者理解其對製造商、醫療保健系統和政策制定者的後續影響。

報告從背景分析轉向策略意義，重點闡述了臨床對及時、可操作結果的需求與商業性對可靠、經濟高效檢測的需求之間的融合。這種整合正在推動對自動化、精益供應鏈和檢測方法多樣性的投資，以適應不同的樣本類型和終端用戶需求。因此，引言部分將該報告定位為相關人員的參考資料，旨在幫助他們調整創新流程、籌資策略和臨床通訊協定，使其與現代尿道感染診斷的實際情況相符。

自動化檢測、分子平台和數位化工作流程的進步如何從根本上重塑尿道感染感染檢測的診斷選擇和臨床路徑

由於技術突破和臨床需求的改變，尿道感染的診斷模式正在發生顯著變化。自動化尿液檢查和自動化顯微鏡檢查提高了檢測通量和重複性，而數位成像和流式細胞技術則提高了尿液沉渣分析的精細度。同時，分子診斷正逐漸走出中心實驗室，等溫擴增和快速PCR檢測縮短了結果獲取時間，並揭示了支持標靶抗菌治療的病原體特異性資訊。次世代定序儀在複雜或復發病例中開始發揮作用，這些病例需要廣泛的病原體檢測和抗藥性分析，但其工作流程和結果解讀方面的要求仍然限制了其常規應用。

同時，快速檢測方法，例如試紙條檢測和簡易顯微鏡檢查，對於分診和即時決策仍然至關重要，尤其是在需要即時採取臨床應對措施的情況下。免疫檢測，包括化學冷光發光法和側向流動檢測，透過提供基於抗原和生物標記的訊號，繼續作為培養方法的補充，有助於初步診療。整合軟體平台的自動化系統支援遠端監控、品管和數據匯總，使實驗室和醫療系統能夠獲得營運洞察並改善診斷管理。

為了適應新型診斷方法和分散式檢查模式，監管和報銷框架也在不斷發展演變，這促使製造商和醫療服務提供者在實際應用中證明其臨床效用和成本效益。總而言之，這些發展是系統性的而非漸進式的，因此需要重新評估實驗室工作流程、人員能力和籌資策略，以便在保持診斷準確性和病人安全的同時，充分利用更快、更特異性的診斷方法。

評估關稅主導的全球貿易和進口成本變化如何改變了診斷檢測領域的供應鏈設計、採購行為和商業策略。

2025年美國關稅調整的累積效應為診斷技術和耗材採購、供應鏈設計以及產品定價帶來了新的考量。國際採購的儀器、試劑和組件進口成本的增加，促使製造商和經銷商重新評估籌資策略，許多企業尋求加快供應商多元化，並將關鍵組裝和試劑的生產轉移到更靠近主要市場的地方。這些轉變正在影響前置作業時間和庫存計劃，因為它們需要在近岸外包和雙重採購的財務和營運成本與供應連續性需求之間取得平衡。

醫院和大型診斷實驗室面臨著最佳化競標流程和重新談判合約的壓力，以減輕不斷上漲的到岸成本的影響。在某些情況下，採購團隊正在延長決策週期，以便將關稅和物流風險的影響納入整體擁有成本分析。關稅環境也影響診斷供應商的定價策略，促使他們對標價進行選擇性調整，並引入捆綁式供應模式，以在合約期間鎖定價格。同時，隨著分銷管道調整以適應不斷變化的利潤結構和運輸經濟，小型診所和居家醫療提供者正在尋求產品供應和服務支援的明確資訊。

在整個生態系統中，我們看到產品設計正朝著減少對稀缺原料依賴的方向發展，試劑配方也更重視穩定性和可運輸性。此外，相關人員正在增加對需求規劃和合約彈性的投入，並利用情境分析來預測監管和關稅波動。這些調整旨在確保患者能夠及時獲得檢測，同時應對貿易保護主義加劇帶來的財務影響，凸顯了在動盪的地緣政治環境下，整合供應鏈和商業策略的重要性。

從測試類型、技術平台、最終用戶優先事項、通路和樣品類型等方面進行深入的觀點，將為有針對性的產品和打入市場策略。

了解市場區隔對於解讀尿道感染診斷全過程的產品和商業性相關性、臨床效用以及應用路徑至關重要。就檢測類型而言，該市場包括自動化尿液檢查方案，例如自動化顯微鏡、數位成像和流式細胞技術，以及培養檢測——後者仍然是病原體分離和藥敏試驗的診斷基礎。分子檢測涵蓋等溫擴增、次世代定序和PCR檢測，每種檢測方法的靈敏度和資訊價值各不相同。同時，快速檢測，例如試紙條檢測和簡化的顯微鏡檢查，可在照護端提供即時分診價值。區分這些檢測類型有助於確定對實驗室自動化、分子檢測能力或即時檢測能力的投資是否能帶來最大的臨床和營運效益。

從技術角度來看，解決方案涵蓋了從全自動或半自動自動化系統到分子診斷的各種方法，包括基於培養的工作流程、化學發光免疫檢測、化學冷光免疫吸附試驗 (ELISA)、側向流動免疫檢測、等溫免疫分析、次世代定序和聚合酶鍊式反應 (PCR)。自動化程度會影響檢測通量、人員配置模式和品管措施，而免疫檢測和分子檢測方法的選擇則決定了可用於抗菌藥物管理工作的診斷資訊的深度。全自動平台和半自動平台之間的選擇通常反映了資本投資能力與靈活、可擴展營運需求之間的平衡。

終端用戶細分——包括診所、診斷實驗室、居家醫療機構和醫院——會影響產品採用時間表和產品組合。診斷實驗室通常優先考慮吞吐量、數據整合和合規性；醫院重視快速的住院決策、與臨床系統的連接以及服務支援；診所優先考慮易用性和周轉時間；而居家照護機構則需要簡化的工作流程、可靠的樣本穩定性以及遠端結果存取。分銷管道——例如直接競標、電子商務、醫​​院藥房和零售藥房——會影響採購速度和通路利潤結構，而樣本類型——例如導尿管插入、中段清潔尿和恥骨上穿刺——則會影響分析前要求和檢測驗證途徑。整合這些細分視角，有助於相關人員根據使用者需求和營運限制，最佳化產品定位、上市後證據產生和商業性推廣。

區域綜合分析臨床需求促進因素、法規環境和基礎設施差異，這些差異決定了全球主要地區的診斷採用模式

區域動態在美洲、中東和非洲以及亞太地區的診斷技術應用、監管預期和分銷模式的形成過程中發揮著至關重要的作用。在美洲，完善的檢測基礎設施、成熟的臨床指南以及對抗菌藥物管理的重視，推動了對先進分子檢測和高通量自動化系統的需求。該地區的綜合醫院系統和大型診斷網路通常優先考慮能夠提供規模經濟效益、數據互通性以及支援臨床營運的服務水平協議的整合平台。同時，採購流程的成熟度和支付方的動態變化會影響技術升級的速度以及對分散式檢查模式的投資意願。

中東和非洲地區情況複雜多樣，既有高通量實驗室和先進的臨床中心，也有資源匱乏的環境。該全部區域的法規結構普遍強調臨床驗證和達到性能標準，而各國的公共衛生重點和報銷途徑則可能存在顯著差異。同時，資源匱乏的環境往往優先考慮成本效益高的快速檢測方法和靈活的工作流程，以便在基礎設施有限的情況下提供可操作的資訊。

亞太地區的特點是即時檢測創新技術的快速普及、公共和私人部門對診斷製造能力的大量投資，以及影響全球供應動態的競爭性製造基礎。擁有強大國內製造能力的國家正在加速開發本地最佳化的檢測方法和系統，跨境監管協調也促進了已驗證產品的快速市場化。在整個全部區域，人口密度、醫療保健服務模式和公共衛生篩檢計畫都會影響居家照護檢測方案、診所快速診斷和集中式分子檢測服務的普及程度。認知到這些區域性因素對於使產品開發重點、市場推廣計劃和夥伴關係模式與區域臨床和商業性實際情況相符至關重要。

檢測創新、整合平台設計和彈性服務模式的領先地位如何決定診斷公司的競爭優勢和夥伴關係策略

尿道感染診斷領域的企業競爭格局受檢測化學創新、平台自動化以及連接性和數據分析等附加價值服務的影響。主要企業往往在多個方面實現差異化，包括儀器可靠性和通量、試劑穩定性和特異性、在分佈式環境下的易用性以及服務和供應鏈網路的穩健性。其策略重點通常包括擴展分子偵測產品組合、提升即時偵測的易用性，以及提供整合硬體、耗材和軟體的捆綁式解決方案，從而建立忠實的採購關係和可預測的收益來源。

夥伴關係和合作在加速技術應用和擴大市場覆蓋範圍方面發揮核心作用。診斷公司正日益與實驗室網路、醫療系統和分銷合作夥伴攜手，試行新的工作流程，展現臨床效用，並達成優先採購協議。此外，模組化產品架構和漸進式功能升級也成為一種趨勢，使客戶無需徹底更換系統即可提升容量和功能。各公司也投資進行多中心臨床評估和真實世界性能研究，以產生證據，為監管申報和與支付方的洽談提供支援。

卓越的服務和可靠的供應仍然是關鍵的競爭優勢，尤其是在關稅波動和全球物流限制的影響下。將在地化生產和策略性庫存佈局與強大的技術支援相結合的公司，能夠更好地維護客戶信任並最大限度地減少停機時間。這些能力共同決定了公司如何優先考慮產品藍圖、商業投資和夥伴關係策略，以滿足多樣化的臨床需求，同時管控營運風險。

為技術開發人員、實驗室負責人和醫療系統負責人提供可操作的策略重點，以確保診斷技術的普及應用、供應的穩定性以及臨床影響。

產業領導者應採取一系列策略行動，齊心協力地利用技術進步，同時保護自身營運免受供應鏈和政策不穩定的影響。首先，產品開發應與臨床應用案例緊密結合，這些案例需能顯著提升診斷速度和抗菌藥物管理效果，並確保證據產生包含實際測試和真實世界性能數據。其次，透過供應商多元化、探索關鍵零件的在地化生產以及採用基於情境的庫存規劃（此規劃需考慮貿易政策變化和物流中斷等因素），增強供應鏈韌性。

第三，優先考慮互通性和軟體驅動的工作流程，以促進與電子健康記錄和實驗室資訊系統的資料整合，從而透過改進臨床決策支援來提升診斷平台的感知價值。第四，根據區域差異調整商業策略：使產品組合和服務模式與醫院、實驗室、診所和居家照護機構的營運能力相匹配，並利用通路夥伴加速在分散市場的推廣。第五，投資上市後支援和培訓項目，以減少營運摩擦，提高檢測性能的一致性，並加強與客戶的長期關係。最後，積極與監管機構和支付方溝通，宣傳臨床效用和成本效益，並推動新型診斷方法納入臨床指南和報銷途徑。這些措施的結合使企業能夠將技術能力與可衡量的臨床和商業性成果聯繫起來。

將採用嚴謹的混合方法，結合相關人員訪談、技術文獻綜合和迭代資料三角驗證，來檢驗診斷效能和應用路徑。

本分析的調查方法整合了多方面的證據，以確保其有效性、透明度和與相關人員的相關性。主要研究包括對臨床醫生、實驗室主任、採購專業人員和行業高管進行結構化訪談，以深入了解推廣應用的促進因素、營運限制和未滿足的需求。次要研究則納入了公開的科學文獻、監管指南、臨床實踐建議和技術產品文檔，以檢驗有關檢測性能、工作流程整合和監管狀態的聲明。

資料綜合依賴於相關人員觀點與已記錄證據之間的迭代三角驗證，並著重研究設計、樣本處理和分析績效指標評估的方法嚴謹性。該方法還繪製了分銷管道、終端用戶工作流程和樣本類型考量圖，以創建實際應用場景，從而指導技術調整和商業策略。該方法的局限性包括報告標準的區域差異以及針對新型診斷方法的不斷變化的監管指南。這些因素透過補充檢驗訪談和專注於操作假設的敏感度分析來解決。在原始資料收集過程中，我們遵守了倫理考量和保密原則，並將所有發現進行綜合，為決策者提供可操作的、基於證據的見解。

本文簡要概述如何協調診斷創新、臨床優先事項和供應保障，以改善患者預後並持續推廣尿道感染檢測。

總之，尿道感染診斷正處於曲折點，技術成熟度、臨床對可操作結果的需求以及供應鏈現狀正在交匯融合，重塑整個醫療保健領域的決策。自動化尿液檢查、先進的分子檢測和即時快速檢測各自發揮獨特而互補的作用，有助於實現更準確、更及時的診斷，並支持抗菌藥物管理工作。貿易政策的轉變和採購慣例的演變共同凸顯了建構具有韌性的供應鏈和商業性可行的產品設計的重要性，從而減少對單一供應來源的依賴。

將臨床證據產生與切實可行的實施策略相結合、投資於互通性和卓越服務、並預見當地監管和報銷複雜性的相關人員，將最有能力把創新轉化為可擴展的臨床影響。最終，需要製造商、實驗室、醫療系統和政策制定者通力合作，才能確保診斷技術的進步在改善患者預後的同時，維持營運和經濟的永續性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合基於智慧型手機的尿液分析應用程式，用於即時尿路感染篩檢
  • 開發用於檢測抗藥性泌尿道感染病原體的照護現場分子診斷技術
  • 推出遠端醫療的家用尿路感染檢測套組，該套裝整合了臨床醫生的回饋資訊。
  • 基於人工智慧的影像分析技術在尿沉渣自動評估的應用
  • 擴展多重PCR檢測板以檢測新出現的多重抗藥性泌尿道感染菌株
  • 利用次世代定序進行全面的尿液微生物組分析，以診斷泌尿道感染。
  • 市場對具有更高特異性的快速測試紙試紙檢測方法的需求日益成長，該方法可用於篩檢無症狀性泌尿道感染。
  • 整合雲端基礎的數據分析，用於基準測試和監控泌尿道感染檢測結果

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依檢測類型尿道感染檢測市場

  • 自動化尿液檢查
    • 自動化顯微鏡
    • 數位影像
    • 流式細胞技術
  • 培養試驗
  • 分子檢測
    • 等溫擴增
    • 次世代定序
    • PCR檢測
  • 快速檢測
    • 試紙測試
    • 顯微鏡

第9章 依技術尿道感染感染檢測市場

  • 自動化系統
    • 全自動
    • 半自動
  • 文化基礎
  • 免疫檢測
    • 化學冷光免疫檢測
    • 伊麗莎
    • 橫向流動化驗
  • 分子診斷
    • 等溫
    • 次世代定序
    • PCR

第10章 依最終用戶尿道感染檢測市場

  • 診所
  • 診斷實驗室
  • 居家照護
  • 醫院

第11章 依分銷管道分類的尿道感染檢測市場

  • 直接競標
  • 電子商務
  • 醫院藥房
  • 零售藥局

第12章 依樣本類型尿道感染檢測市場

  • 導管插入
  • 中游清潔捕撈
  • 恥骨上吸力

第13章 各地區尿道感染檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章尿道感染檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國尿道感染檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Danaher Corporation
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Sysmex Corporation
    • Ortho Clinical Diagnostics, Inc.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
Product Code: MRR-7C50F27396DF

The Urinary Tract Infection Testing Market is projected to grow by USD 2.15 billion at a CAGR of 4.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.47 billion
Estimated Year [2025] USD 1.54 billion
Forecast Year [2032] USD 2.15 billion
CAGR (%) 4.90%

A concise framing of how clinical demand, technological advances, and supply chain dynamics are reshaping urinary tract infection testing pathways for decision-makers

This executive summary opens with a clear view of the evolving diagnostic environment for urinary tract infections, where clinical priorities, technological innovation, and supply chain realities intersect to shape decision-making across healthcare settings. Diagnostic stewardship, an escalating focus on rapid and accurate pathogen identification, and the imperative to curb antimicrobial resistance are recalibrating how clinicians, laboratorians, and procurement leaders evaluate testing modalities. As a result, diagnostic pathways are shifting from empirical treatment toward evidence-based interventions informed by faster, more specific testing approaches.

The introduction frames the primary vectors of change in the field: technological maturation of automated and molecular platforms, the proliferation of point-of-care solutions, and integration of digital workflows that streamline sample-to-result timelines. It also considers the operational context in which these diagnostics are deployed, from hospitals and diagnostic laboratories to clinic networks and home-care settings, emphasizing the need for interoperability, quality assurance, and scalable implementation. By situating recent advances within the broader clinical, regulatory, and economic landscape, this section prepares the reader to appreciate the downstream implications for manufacturers, health systems, and policy makers.

Transitioning from background to strategic implications, the text highlights the convergence of clinical demand for timely, actionable results with commercial imperatives to deliver reliable, cost-efficient testing. This alignment is driving investment in automation, lean supply chains, and assay versatility that can meet diverse sample types and end-user requirements. The introduction therefore positions the report as a resource for stakeholders seeking to align innovation pipelines, procurement strategies, and clinical protocols to the realities of contemporary urinary tract infection diagnostics.

How converging advances in automated analytics, molecular platforms, and digital workflows are fundamentally reworking diagnostic choices and clinical pathways in urinary tract infection testing

The landscape for urinary tract infection diagnostics is undergoing transformative shifts driven by technological breakthroughs and changing clinical expectations. Automated urinalysis and automated microscopy are delivering greater throughput and reproducibility, while digital imaging and flow cytometry are refining the granularity of sediment analysis. Concurrently, molecular diagnostics are moving beyond centralized laboratories as isothermal amplification and rapid PCR assays shorten time-to-result and uncover pathogen-specific information that supports targeted antimicrobial therapy. Next generation sequencing is beginning to play a role in complex or recurrent cases where broad pathogen detection and resistance profiling are needed, although its routine use remains selective due to workflow and interpretation demands.

At the same time, rapid tests such as dipstick assays and simplified microscopy retain relevance for triage and point-of-care decision-making, particularly in settings where immediate clinical action is necessary. Immunoassays, including chemiluminescent formats and lateral flow devices, continue to complement culture-based approaches by delivering antigen or biomarker-based signals that inform initial management. These technological shifts are paralleled by digitization trends: automated systems with integrated software platforms support remote monitoring, quality control, and data aggregation, enabling laboratories and health systems to extract operational insights and improve diagnostic stewardship.

Regulatory and reimbursement frameworks are also evolving to accommodate novel diagnostics and decentralized testing models, prompting manufacturers and health providers to demonstrate clinical utility and cost-effectiveness in pragmatic settings. Taken together, these developments are not incremental but systemic-prompting reassessment of laboratory workflows, workforce competencies, and procurement strategies to capitalize on faster, more specific diagnostics while maintaining diagnostic accuracy and patient safety.

Assessing how tariff-driven changes to global trade and import costs have altered supply chain design, procurement behavior, and commercial strategies in diagnostic testing

The cumulative impact of tariff changes enacted in the United States in 2025 has introduced new considerations across procurement, supply chain design, and product pricing for diagnostic technologies and consumables. Increased import costs for instruments, reagents, and components sourced internationally have led manufacturers and distributors to re-evaluate sourcing strategies, with many accelerating supplier diversification and exploring relocation of critical assembly or reagent production closer to primary markets. These shifts have, in turn, affected lead times and inventory planning as organizations balance the need for supply continuity against the financial and operational costs of nearshoring or dual-sourcing arrangements.

Hospitals and large diagnostic laboratories have experienced pressure to optimize tendering processes and to renegotiate contracts to mitigate the impact of higher landed costs. In some instances, procurement teams have extended decision cycles to incorporate total cost of ownership analyses that include tariff exposure and logistics risk. The tariff environment has also influenced pricing strategies for diagnostic vendors, prompting selective adjustment of list prices or the introduction of bundled supply models that lock in pricing for defined contract durations. Meanwhile, smaller clinics and home-care providers have sought greater clarity on product availability and service support as distribution channels adapt to changing margin structures and shipping economics.

Across the ecosystem, there is an observable pivot toward product designs that reduce reliance on hard-to-source inputs and to reagent formulations that emphasize stability and transportability. Additionally, stakeholders are investing more in demand planning and contract resilience, using scenario analysis to anticipate regulatory or tariff fluctuations. These adaptations collectively aim to preserve patient access to timely testing while managing the financial implications of a more protectionist trade posture, underscoring the importance of integrated supply chain and commercial strategies in a volatile geopolitical environment.

Deep segmentation perspective that aligns test types, technological platforms, end-user priorities, distribution pathways, and sample types to inform targeted product and go-to-market strategies

Understanding segmentation is critical to interpreting product-commercial fit, clinical utility, and adoption pathways across the urinary tract infection diagnostic continuum. When considering test type, the market encompasses automated urinalysis options that include automated microscopy, digital imaging, and flow cytometry, alongside culture tests that remain the diagnostic backbone for pathogen isolation and susceptibility testing. Molecular tests span isothermal amplification, next generation sequencing, and PCR assays, each offering distinct sensitivity and informational value, while rapid tests such as dipstick assays and simplified microscopy provide immediate triage value in point-of-care contexts. These test-type distinctions inform decisions about where investments in laboratory automation, molecular capacity, or point-of-care capabilities deliver the greatest clinical and operational returns.

From a technology standpoint, solutions range from automated systems that can be fully automated or semi-automated to culture-based workflows, immunoassays including chemiluminescent immunoassay, ELISA, and lateral flow formats, and molecular diagnostics that utilize isothermal methods, next generation sequencing, and PCR. The degree of automation influences throughput, staffing models, and quality control practices, while immunoassay and molecular options determine the depth of diagnostic information available for antimicrobial stewardship initiatives. Selecting between fully automated and semi-automated platforms often reflects a balance between capital investment capacity and the need for flexible, scalable operations.

End-user segmentation-clinics, diagnostic laboratories, home care settings, and hospitals-shapes adoption timelines and product configuration. Diagnostic laboratories typically prioritize throughput, data integration, and compliance features; hospitals emphasize rapid inpatient decision-making, connectivity with clinical systems, and service support; clinics value ease of use and turnaround time; and home care environments require simplified workflows, robust sample stability, and remote result access. Distribution channels such as direct tender, e-commerce, hospital pharmacy, and retail pharmacy influence procurement velocity and channel margin structures, while sample type considerations-catheterized, midstream clean catch, and suprapubic aspiration-affect pre-analytical requirements and assay validation pathways. Integrating these segmentation lenses enables stakeholders to refine product positioning, post-market evidence generation, and commercial outreach tailored to user needs and operational constraints.

A regional synthesis of clinical demand drivers, regulatory environments, and infrastructure variations that determine diagnostic adoption patterns across major global territories

Regional dynamics play a defining role in shaping diagnostic adoption, regulatory expectations, and distribution models across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, robust laboratory infrastructure, established clinical guidelines, and emphasis on antimicrobial stewardship drive demand for advanced molecular assays and high-throughput automated systems. The region's consolidated hospital systems and large diagnostic networks often prioritize integrated platforms that offer economies of scale, data interoperability, and service-level agreements that support continuous clinical operations. Meanwhile, procurement sophistication and payer dynamics influence the cadence of technology upgrades and the willingness to invest in decentralized testing modalities.

Europe Middle East & Africa presents a heterogeneous landscape where high-capacity laboratories and advanced clinical centers coexist with resource-constrained settings. Regulatory frameworks across the region place a premium on clinical validation and conformity with performance standards, while national public health priorities and reimbursement pathways can vary markedly. In higher-resource markets, there is growing adoption of molecular diagnostics and automation, whereas in lower-resource settings the emphasis often remains on cost-effective, rapid tests and adaptable workflows that deliver actionable information with limited infrastructure.

Asia-Pacific is characterized by rapid adoption of point-of-care innovation, significant public and private investment in diagnostics capacity, and a competitive manufacturing base that influences global supply dynamics. Countries with sizeable domestic manufacturing capabilities are accelerating development of locally optimized assays and systems, and cross-border regulatory harmonization efforts are fostering faster market entry for validated products. Across the region, population density, healthcare access models, and public health screening programs inform differential uptake of home-care testing solutions, clinic-based rapid diagnostics, and centralized molecular services. Recognizing these region-specific drivers is essential for aligning product development priorities, market access plans, and partnership models with local clinical and commercial realities.

How leadership in assay innovation, integrated platform design, and resilient service models is determining competitive advantage and partnership strategies among diagnostic companies

Competitive dynamics among companies operating in urinary tract infection diagnostics are shaped by innovation in assay chemistry, platform automation, and value-added services such as connectivity and data analytics. Key players tend to differentiate along multiple axes: instrument reliability and throughput, reagent stability and specificity, ease of use for decentralized settings, and the robustness of service and supply networks. Strategic priorities often include expanding molecular testing portfolios, improving point-of-care usability, and offering bundled solutions that integrate hardware, consumables, and software to create locked-in procurement relationships and predictable revenue streams.

Partnerships and collaborations play a central role in accelerating technology adoption and expanding market reach. Diagnostic companies increasingly align with laboratory networks, health systems, and distribution partners to pilot new workflows, demonstrate clinical utility, and secure preferred purchasing arrangements. There is also a trend toward modular product architectures that allow incremental capability upgrades, enabling customers to ramp capacity and functionality without wholesale system replacement. Additionally, companies are investing in evidence generation through multi-center clinical evaluations and real-world performance studies to support regulatory submissions and payer conversations.

Service excellence and supply reliability remain critical competitive differentiators, particularly in environments affected by tariff volatility and global logistics constraints. Firms that combine local manufacturing or strategic inventory positioning with robust technical support are better positioned to maintain customer trust and minimize downtime. Collectively, these capabilities inform how organizations prioritize product roadmaps, commercial investments, and partnership strategies to meet diverse clinical needs while managing operational risk.

Actionable strategic priorities for technology developers, laboratory leaders, and health system purchasers to secure adoption, supply resilience, and clinical impact in diagnostics

Industry leaders should pursue a coordinated set of strategic actions to capitalize on technological advancements while insulating operations from supply chain and policy volatility. First, align product development with clinical use cases that demonstrate clear improvements in diagnostic timeliness and antimicrobial stewardship outcomes, ensuring that evidence generation includes pragmatic trials and real-world performance data. Second, build supply chain resilience by diversifying suppliers, exploring localized manufacturing for critical components, and employing scenario-based inventory planning that accounts for trade policy shifts and logistics disruptions.

Third, prioritize interoperability and software-enabled workflows that facilitate data integration with electronic health records and laboratory information systems, thereby increasing the perceived value of diagnostic platforms through improved clinical decision support. Fourth, tailor commercial strategies to regional nuances: adapt product configurations and service models to the operational capabilities of hospitals, laboratories, clinics, and home-care providers, and leverage channel partners to accelerate adoption in fragmented markets. Fifth, invest in post-market support and training programs that reduce operational friction, enhance assay performance consistency, and strengthen long-term customer relationships. Finally, engage proactively with regulators and payers to communicate clinical utility and cost-effectiveness, positioning novel diagnostics for inclusion in clinical guidelines and reimbursement pathways. These combined actions will help organizations translate technical capabilities into measurable clinical and commercial outcomes.

A rigorous mixed-methods approach combining stakeholder interviews, technical literature synthesis, and iterative data triangulation to validate diagnostic performance and adoption pathways

The research methodology underpinning this analysis integrates multiple evidence streams to ensure validity, transparency, and relevance to stakeholders. Primary research included structured interviews with clinicians, laboratory directors, procurement professionals, and industry executives, providing qualitative insights into adoption drivers, operational constraints, and unmet needs. Secondary research incorporated publicly available scientific literature, regulatory guidance, clinical practice recommendations, and technical product documentation to triangulate claims around assay performance, workflow integration, and regulatory status.

Data synthesis relied on iterative triangulation between stakeholder perspectives and documented evidence, with attention to methodological rigor in evaluating study design, sample handling, and analytical performance metrics. The approach also involved mapping distribution channels, end-user workflows, and sample-type considerations to create realistic use-case scenarios that inform technology fit and commercial strategy. Limitations of the methodology include variability in regional reporting standards and the evolving nature of regulatory guidance for novel diagnostics; these factors were addressed through supplemental validation interviews and sensitivity analyses focused on operational assumptions. Ethical considerations and confidentiality protections were upheld during primary data collection, and all findings were synthesized to provide actionable, evidence-based insights for decision-makers.

A concise synthesis of how diagnostic innovation, clinical priorities, and supply resilience must align to realize improved patient outcomes and sustained adoption in urinary tract infection testing

In conclusion, urinary tract infection diagnostics are at an inflection point where technological maturation, clinical demand for actionable results, and supply chain realities converge to reshape decision-making across healthcare settings. Automated urinalysis, advanced molecular testing, and point-of-care rapid assays each occupy distinct but complementary roles in enabling more accurate, timely diagnosis and supporting antimicrobial stewardship efforts. The compounded effects of trade policy changes and shifting procurement practices have underscored the need for resilient supply chains and commercially viable product designs that reduce dependence on single-source inputs.

Stakeholders who integrate clinical evidence generation with pragmatic implementation strategies, who invest in interoperability and service excellence, and who anticipate regional regulatory and reimbursement complexities will be best positioned to translate innovation into scalable clinical impact. Ultimately, the path forward requires coordinated action across manufacturers, laboratories, health systems, and policy makers to ensure that diagnostic advances deliver improved patient outcomes while maintaining operational and economic sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of smartphone-based urine analysis apps for real-time UTI screening
  • 5.2. Development of point-of-care molecular diagnostics for antibiotic-resistant UTI pathogens
  • 5.3. Adoption of telehealth-enabled home UTI testing kits with integrated clinician feedback
  • 5.4. Implementation of AI-powered image analysis for automated urinary sediment evaluation
  • 5.5. Expansion of multiplex PCR panels detecting emerging multidrug-resistant UTI strains
  • 5.6. Use of next-generation sequencing for comprehensive urinary microbiome profiling in UTI diagnosis
  • 5.7. Rising demand for rapid dipstick tests with improved specificity for asymptomatic UTI screening
  • 5.8. Integration of cloud-based data analytics for UTI test result benchmarking and surveillance

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urinary Tract Infection Testing Market, by Test Type

  • 8.1. Automated Urinalysis
    • 8.1.1. Automated Microscopy
    • 8.1.2. Digital Imaging
    • 8.1.3. Flow Cytometry
  • 8.2. Culture Test
  • 8.3. Molecular Test
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Next Generation Sequencing
    • 8.3.3. Pcr Assay
  • 8.4. Rapid Test
    • 8.4.1. Dipstick Test
    • 8.4.2. Microscopy

9. Urinary Tract Infection Testing Market, by Technology

  • 9.1. Automated Systems
    • 9.1.1. Fully Automated
    • 9.1.2. Semi Automated
  • 9.2. Culture Based
  • 9.3. Immunoassays
    • 9.3.1. Chemiluminescent Immunoassay
    • 9.3.2. Elisa
    • 9.3.3. Lateral Flow Assay
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal
    • 9.4.2. Next Generation Sequencing
    • 9.4.3. Pcr

10. Urinary Tract Infection Testing Market, by End User

  • 10.1. Clinics
  • 10.2. Diagnostic Laboratories
  • 10.3. Home Care
  • 10.4. Hospitals

11. Urinary Tract Infection Testing Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. E Commerce
  • 11.3. Hospital Pharmacy
  • 11.4. Retail Pharmacy

12. Urinary Tract Infection Testing Market, by Sample Type

  • 12.1. Catheterized
  • 12.2. Midstream Clean Catch
  • 12.3. Suprapubic Aspiration

13. Urinary Tract Infection Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Urinary Tract Infection Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Urinary Tract Infection Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Danaher Corporation
    • 16.3.4. Siemens Healthineers AG
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. bioMerieux SA
    • 16.3.7. Sysmex Corporation
    • 16.3.8. Ortho Clinical Diagnostics, Inc.
    • 16.3.9. QIAGEN N.V.
    • 16.3.10. Bio-Rad Laboratories, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. URINARY TRACT INFECTION TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. URINARY TRACT INFECTION TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. URINARY TRACT INFECTION TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIGITAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIGITAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIGITAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIGITAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIGITAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIGITAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIPSTICK TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIPSTICK TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIPSTICK TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIPSTICK TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIPSTICK TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIPSTICK TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FULLY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FULLY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FULLY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FULLY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FULLY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY FULLY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SEMI AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SEMI AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SEMI AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SEMI AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SEMI AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SEMI AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY ISOTHERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY E COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY E COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CATHETERIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CATHETERIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CATHETERIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CATHETERIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CATHETERIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY CATHETERIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MIDSTREAM CLEAN CATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MIDSTREAM CLEAN CATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MIDSTREAM CLEAN CATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MIDSTREAM CLEAN CATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MIDSTREAM CLEAN CATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY MIDSTREAM CLEAN CATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUPRAPUBIC ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUPRAPUBIC ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUPRAPUBIC ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUPRAPUBIC ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUPRAPUBIC ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUPRAPUBIC ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL URINARY TRACT INFECTION TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED URINALYSIS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY RAPID TEST, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032